In fact, it was initially tested in refractory metastatic melanoma patients, in which the use of TILs that were extracted and then rapidly expanded with feeder cells and high doses of IL-2 [75], revealed capable of generating enough cells for reinfusion. Here, IL2 is linked to metastatic melanoma.